For instance, the first clinically-applied targeted therapy was Herceptin, a monoclonal antibody against receptor tyrosine kinase HER2 and approved by the FDA for treating patients with HER2-positive BC in 1998 [35]. The gene discussed is ERBB2; the disease is breast cancer.